Market Newsdesk

Stem to Launch 12 New Products in January Featuring
, Cannabis-Infused Topicals,
and a new CBD Product Line-Up from Patent Edibles -Pending Hemp Genetics

Acquisition of Driven Deliveries to Support Distribution Drive

BOCA RATON, FL, Dec. 08, 2020 (GLOBE NEWSWIRE) — Stem Holdings, Inc. (OTCQX: STMHCSE:STEM), a leading vertically-integrated cannabis and hemp branded products company with state-of-the-art cultivation, processing, extraction, retail, and distribution operations throughout the United States, announced that they will be starting 2021 with an exciting line-up of disruptive products beginning in Oregon and launching in all markets in which Stem operates. Stem has added a cutting-edge extraction laboratory to its commercial kitchen capabilities for full integration in production of these value-added, margin-accretive products. The pending acquisition of Driven Deliveries, Inc. later this month (OTCQB: DRVD) will support new distribution in current and new markets.

Cannavore^™ Cannabis Confections – Just in time for the holidays, Stem’s Cannavore is launching two flavors for its award-winning caramels – Irish Cream and Hazelnut – two on trend flavors complementing our original Salted Caramel. Made with full spectrum solventless bubble hash, they are rich in cannabinoids and terpenes for consistent dosing and effectiveness.

Dose-ology^™ Topicals – To condition skin all year round, Stem’s Dose-ology brand is launching its first cannabis-infused topicals featuring lotion, massage oil, and facial serum. Made with THC concentrate from Stem’s own TJ Gardens award-winning brand of cannabis, Dose-ology will feature the exact dose recommended by Stem Medical Holdings’ team led by Dr. Drore Eisen, to assure consumers that they will experience optimal products benefits with each and every usage.

Dose-ology^™ CBD Topicals – Dose-ology will also enter the mass market with a line-up of four new broad-spectrum CBD-infused topical products that reflect Stem’s commitment to efficacious dosing and performance. They will initially be sold at select retailers and in e-commerce. The hemp grown for these products features patent-pending genetics that resist powdery mildew, and continues to be part of Stem’s work with Cornell University’s School of Agriculture.

“This is just the beginning of a new queue of disruptive products unlike any other company’s,” stated Adam Berk, CEO of Stem. “Our vertical integration from seed to extraction to production of finished goods distinguishes us from other brands in the marketplace, particularly as we leverage the expertise of our experience grow and extraction teams, and our increasing ability to fill distribution white space along with the upcoming direct-to-consumer capability offered by Driven.” He continued, “We will be closing on our acquisition of Driven this month and this will be a critical component of our go-to-market strategy, as will strategic collaborations to enthuse the market,” Berk concluded.

About Stem Holdings, Inc.

Stem Holdings, Inc. (OTCQX: STMH CSE: STEM) is a leading cannabis and hemp branded products company in the U.S. with proprietary capabilities in sustainable cultivation, processing, extraction, and R&D, as well as retail and distribution operations aligned with state-by-state regulations. Stem’s award-winning brands are the foundation of the Company’s expansion into current and new segments and markets, with exceptional and disruptive brands and products that benefit well-being. Stem’s expertise and scale will drive growth domestically and internationally, building value for shareholders.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the management of Stem with respect to future business activities. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and include information regarding: (i) the ability of the Company to successfully achieve its business objectives, (ii) plans for expansion of Stem, (iii) expectations for other economic, business, and/or competitive factors, and (iv) anticipated growth.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the management of Stem’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Stem believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws, including those related to taxation; the inability to locate and acquire suitable companies, properties and assets necessary to execute on the Company’s business plans; and increasing costs of compliance with extensive government regulation. This forward-looking information may be affected by risks and uncertainties in the business of Stem and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Stem has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Stem does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has in any way passed upon the merits of the proposed transactions described in this news release or has approved or disapproved of the contents of this news release.

For further information, please contact:
Media Contact:
Mauria Betts
STEM HOLDINGS, INC.
[email protected]
971.319.0303

Attachment

• Stem Holdings, Inc

Presentation on Tuesday December 15^th at 11:00am EST

LOS ANGELES, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it will be presenting at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15, 2020 at 11:00 AM EST / 8:00 AM PST. Amro Albanna, Co-founder and Chief Executive Officer of Aditxt, will be presenting to a live, virtual audience. 

Register here:


ve.mysequire.com/

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts. 

“The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform. 

View Aditxt’s profile here:


http://www.ldmicro.com/profile/ADTX

Profiles powered


by LD Micro

About Aditx Therapeutics

Aditxt is developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring biotechnology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming biotechnology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

About LD Micro/SEQUIRE

LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.

The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe. 

In September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:

PCG Advisory
Jeff Ramson
Chief Executive Officer
[email protected]
646-762-4518
www.aditxt.com

Source: Aditxt via LD Micro

NOT FOR DISTRIBUTION TO US NEWS WIRE SERVICES OR FOR DISSEMINATON INTO THE USA

VANCOUVER, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) — Independence Gold Corp. (TSX.V: IGO) (the “Company”) wishes to announce a proposed equity financing (the “Financing”) comprised of 6,250,000 flow-through common shares (the “FT Shares”) at a price of $0.16 per FT Share, for aggregate proceeds of $1,000,000; and 3,571,428 additional common shares (each a “Unit”) at a price of $0.14 per Unit for aggregate proceeds of $500,000. Each Unit will consist of one common share of the Company (a “Share”) and one half of one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one additional Share at an exercise price of $0.20 per common share for a period of 24 months. Subject to compliance with applicable securities laws and the approval of the Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.

The net proceeds from the Offering will be used by the Company to fund a winter drill program at the 3Ts Property, expected to commence in February 2021, and may also be used for general and administrative purposes.

Closing of the Offering is subject to receipt of applicable regulatory approvals including the approval of the TSX Venture Exchange. The securities issued will be subject to a standard four month hold period.

ON BEHALF OF THE BOARD of Independence Gold Corp.

“Randy Turner”

Randy Turner, President and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to Independence within the meaning of applicable securities laws, including statements with respect to the Company’s planned drilling and exploration activities. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in Independence’s public filings under Independence Gold Corp.’s SEDAR profile at

www.sedar.com

.  Although Independence has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Independence disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

UNITED STATES ADVISORY. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), have been offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

For further information please contact Randy Turner at 604-687-3959 or [email protected]. 

 

HPN424
has
show
n
confir
med partial response in treatment of
metastatic castration
–
resistant prostate cancer
in highest
fixed
dose cohort
(160 ng/kg)
of continuing Phase 1
/2a
d
o
se escalation
trial

Three of seven patients in highest
fixed
dose HPN424 cohort have shown PSA reduction

D
ose escalation
trials
advancing for HPN536 and HPN217 with initial data readouts
and
initiation of expansion cohorts
expected in 2021

Management to host
clinical
update
webcast/
c
all
today,
D
ecember
8
, 2020
,
at 8
a.m. ET

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) —  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update and reported a confirmed partial response based on RECIST v1.1 criteria for its most advanced program, HPN424 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). As of December 1, 2020, in the 160ng/kg cohort, which is the highest fixed dose tested to date, 7 patients have been enrolled and one patient has achieved a confirmed partial response. In addition, 3 patients enrolled in this cohort had serum PSA reductions, including one with a reduction of 50% (PSA50). Dose escalation continues in this trial, in the Phase 1/2a clinical trials for HPN536 as a treatment for ovarian cancer and other mesothelin-expressing solid tumors and in the HPN217 Phase 1/2 clinical trial for multiple myeloma. Step dosing is being utilized in all programs to accelerate testing of higher doses. Dosing of the first patient in the Phase 1/2 trial for Harpoon’s fourth TriTAC development program, HPN328, in small cell lung cancer and other DLL3-associated tumors is expected to occur by the end of the year.

”We are pleased to provide a trial update to our shareholders today, as well as outline our expectations for 2021. We have made significant progress in all of our clinical development programs in 2020,” stated Gerald McMahon, Ph.D., President and CEO of Harpoon Therapeutics. “We are excited to report our first confirmed partial response in the continuing dose escalation trial for HPN424, especially in a heavily pretreated patient population with advanced metastatic disease. We are also excited by the potential for multiple data releases in 2021 on all four of our programs, which we believe represent meaningful milestones for our company.”

“We are pleased to report the activity we are seeing with HPN424 in late-stage prostate cancer patients in our highest fixed dose cohort tested to date,” said Natalie Sacks, M.D., Chief Medical Officer of Harpoon. “We are implementing step dosing in all of our programs, which allows rapid escalation to higher doses. We look forward to sharing data from these higher-dose cohorts in 2021.”

Clinical Program Updates

(All data as of December 1, 2020)

Dose escalation
continues
in Phase 1/2
a
trial for HPN424 in the treatment of
mCRPC
. As of the December 1, 2020 data cutoff date, 69 patients have been dosed across 14 cohorts at fixed doses of 1.3 to 160ng/kg and in step dosing cohorts up to 300ng/kg administered as a weekly intravenous infusion. Enrolled patients had a median of 6 prior systemic therapies, and 76% of patients had prior chemotherapy in the metastatic castration-resistant setting. Ten of 44 patients (23%) with treatment start dates at least 6 months ago remained on study treatment for more than 24 weeks.

At the highest fixed dose tested to date, 160ng/kg, one patient out of 7 has experienced a confirmed partial response with tumor lesion reduction of 43%, and 3 of 7 patients have had serum PSA declines from baseline, including one patient with a PSA reduction greater than 50%.

HPN424 was generally well tolerated and cytokine-related adverse events have been manageable. Reported Grade 3 or higher adverse events have included cytokine release syndrome (CRS) (10%), ALT increase (11%) and AST increase (11%). CRS events and transaminitis have been transient and have not resulted in treatment discontinuation. Dose-limiting toxicities (DLTs) have been observed and have not limited escalation. A maximum tolerated dose (MTD) has not been identified. Presentation of Phase 1 data and initiation of an expansion cohort is planned for the first half of 2021. Interim data from this expansion cohort is anticipated by the end of 2021.

HPN536
(
mesothelin
TriTAC
)
Phase 1/2a clinical trial
continues escalation. Dosing has occurred across 9 fixed-dose cohorts of 6 to 280ng/kg and 1 step dose cohort up to 600ng/kg. Tumor types treated include late-stage ovarian and pancreatic cancers and peritoneal mesothelioma. Enrolled patients had a median of four prior systemic therapies, and 66% of patients had progressive disease as best response to their most recent prior therapy. Pharmacokinetic analysis shows median half-life of more than 70 hours. Among the relapsed/refractory ovarian cancer patients with at least one post-baseline scan, 8 of 12 (67%) patients showed stability of target lesions.

HPN536 appears to be well tolerated. One CRS grade 3 occurred in the absence of dexamethasone premedication treatment. The CRS resolved, and the patient continued on study with dexamethasone premedication. As of December 1, 2020, no DLTs have been observed. Initiation of an expansion cohort is anticipated by the second half of 2021, with a presentation of Phase 1 data by year-end 2021.

Dose escalation for HPN217
(BCMA
TriTAC
)
Phase 1/2 clinical trial progressing
rapidly
. Relapsed/refractory multiple myeloma patients have been treated across 6 single-patient fixed dose cohorts of 5 to 810µg, reflecting a more than 100-fold increase in dose in 8 months. HPN217 has been well-tolerated, and no DLTs have been observed as of the December 1, 2020 cutoff date. A presentation of interim data is anticipated in 2021, with initiation of a dose expansion cohort in the second half of 2021.

First patient dosing anticipated for HPN
328 (DLL3
TriTAC
)
by the end of 2020. The first site is open and recruiting for the dose escalation portion of this Phase 1/2 clinical trial. In the first cohort, the patients will receive a flat dose of 15µg of HPN328 administered once weekly by intravenous infusion. Eligible patients include small cell lung cancer patients who have relapsed after platinum chemotherapy and patients with other tumors associated with DLL3 expression. Presentation of initial data is planned for the second half of 2021.

Webcast and Conference Call

Harpoon’s management will host a webcast and conference call at 8 a.m. ET / 5 a.m. PT on December 8, 2020. The live call may be accessed by dialing (866) 951-6894 for domestic callers and (409) 216-0624 for international callers with conference ID code number 1388395. A webcast of the live call will be available online in the investor relations section of the Harpoon website at www.harpoontx.com. A replay of the webcast will be available shortly after the event and can be accessed at the same weblink.

About
Harpoon
Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC^®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1/2 trial in the fourth quarter of 2020. Harpoon has also developed a proprietary ProTriTAC^TM platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope, design and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, and the timing of development milestones for product candidates. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials, the risk that trials may be delayed and may not have satisfactory outcomes, and unexpected litigation or other disputes that impede clinical trial progress. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts
:

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
[email protected]

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
[email protected]

LYON, France and NEWTON, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration whereby both companies will work together to test and optimize growth hormone receptor antagonist (GHRA) peptides, with the goal of selecting a candidate for clinical development as a potential treatment for acromegaly, a rare but serious endocrine disorder with significant unmet medical need. Amolyt has also acquired an option to license the identified candidates for future clinical development.

“We are pleased to partner with PeptiDream, a leading Japanese biopharmaceutical company with an impressive technology platform for the design of new therapeutic peptides, and whose strategic partners include world class pharmaceutical companies,” stated Thierry Abribat, Ph.D., chief executive officer of Amolyt Pharma. “The potential expansion of our pipeline into acromegaly, where significant unmet need persists, represents a perfect strategic fit for Amolyt. Given our extensive experience in developing therapeutic peptides, including AZP-3601, our lead clinical candidate for hypoparathyroidism, we will leverage our expertise to bring a promising therapy to acromegaly patients in need.”    

Patrick Reid, chief executive officer of PeptiDream Inc., added, “We believe Amolyt Pharma is the ideal partner to lead the development of our small peptide GHRA platform and to potentially bring an improved treatment paradigm to patients suffering from acromegaly. We are impressed by Amolyt’s therapeutic peptide development capabilities and we are confident in entrusting them with advancing this potentially important asset. We look forward to a mutually beneficial partnership.”

About Acromegaly
Acromegaly is a rare chronic endocrine disorder that is typically caused by an adenoma (benign tumor) of the pituitary gland, and that is characterized by excessive production of growth hormone (GH), resulting in abnormally high levels of insulin-like growth factor-1 (IGF-1). Common features include enlargement of the hands, feet and jaw. Medical complications include cardiovascular disease, cardiomyopathy that can potentially lead to heart failure, impaired glucose tolerance with subsequent development of diabetes, hypogonadism, bone and joint disease, cerebrovascular events, sleep apnea and impaired respiratory function. The mean age of diagnosis is 40-45 years, but it is often diagnosed 4-10 years after onset due to its slow progression. It is estimated that there are 26,000 acromegaly patients in the U.S. and an additional 35,000 in the E.U.

About
Amolyt
Pharma 

Amolyt Pharma is building on its team’s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Its portfolio includes AZP-3601, a potential treatment for hypoparathyroidism, and AZP-3404, which is undergoing indication prioritization work. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit www.amolytpharma.com or follow us on Twitter at @AmolytPharma.

At
Amolyt
:

Media:

Cherilyn Cecchini, M.D.
LifeSci Communications
[email protected]
+1.646.876.5196

Investors:

Ashley Robinson
LifeSci Advisors, LLC
[email protected]
+1.617.430.7577

JERSEY CITY, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) — Verisk (Nasdaq:VRSK), a leading data and analytics company, announced today that Nationwide has joined the Verisk Cyber Data Exchange as part of a growing effort across the insurance industry to gain new insights into the rapidly changing world of cyber risk.

By joining the Verisk Cyber Data Exchange, Nationwide will contribute premium and loss records to an expanding pool of aggregated, anonymized insurance data from participating cyber insurers around the world. In return, Nationwide will obtain access to an interactive platform powered by the Exchange and be able to use its robust analytics to better manage risks, develop products, build models, and guide strategic planning.

“Understanding industry-wide cyber exposure and developing insights into pricing and loss trends is a major challenge in today’s dynamic cyber risk landscape,” said Catherine Rudow, Nationwide’s E&S/Specialty vice president of cyber insurance. “Joining the Verisk Cyber Data Exchange will improve our access to critical cyber insurance data and risk information, enabling us to deliver more robust cyber protections and further expand our leading risk solutions for consumers and businesses of all sizes.”

“Improving the collective understanding of cyber risk is a critical step toward building a thriving marketplace for cyber insurance coverages that ultimately protect consumers and businesses alike,” said Prashant Pai, vice president and general manager, Verisk Cyber Solutions. “With leading insurers like Nationwide participating in this important initiative, we can provide one-of-a-kind market intelligence to insurers looking to provide or enhance their cyber risk solutions.”

The Cyber Data Exchange is a part of Verisk’s Cyber Solutions Suite, an end-to-end ecosystem that can help insurers and reinsurers more quickly deliver new cyber programs or enhance existing solutions. Powered by data on more than 100 million organizations worldwide, the suite provides a wide range of products and services, including a pricing, underwriting, and distribution platform; advisory policy language and loss costs; an applicant analytics and scoring solution; a portfolio visualization engine; and aggregation management modeling for cyber risk.

To learn more about the Verisk Cyber Data Exchange, please visit: https://www.verisk.com/insurance/products/cyber-data-exchange/

To learn more about Nationwide’s cyber security offerings, please visit: https://mls.nationwideexcessandsurplus.com/fs/products/cyber-and-professional-liability/

About Verisk 

Verisk (Nasdaq:VRSK) is a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services. Using advanced technologies to collect and analyze billions of records, Verisk draws on unique data assets and deep domain expertise to provide first-to-market innovations that are integrated into customer workflows. Verisk offers predictive analytics and decision support solutions to customers in rating, underwriting, claims, catastrophe and weather risk, global risk analytics, natural resources intelligence, economic forecasting, and many other fields. Around the world, Verisk helps customers protect people, property, and financial assets.

Headquartered in Jersey City, N.J., Verisk operates in 30 countries and is a member of Standard & Poor’s S&P 500^® Index and part of the Nasdaq 100 Index.

In 2018 and 2019, Forbes magazine named Verisk to its World’s Best Employers list. For more information, please visit www.verisk.com.

About Nationwide

Nationwide, a Fortune 100 company based in Columbus, Ohio, is one of the largest and strongest diversified insurance and financial services organizations in the United States. Nationwide is rated A+ by both A.M. Best and Standard & Poor’s. An industry leader in driving customer-focused innovation, Nationwide provides a full range of insurance and financial services products including auto, business, homeowners, farm and life insurance; public and private sector retirement plans, annuities and mutual funds; excess & surplus, specialty and surety; pet, motorcycle, and boat insurance. For more information, visit www.nationwide.com. Follow us on Facebook and Twitter.

# # # #

Media Contacts:

Joseph Madden
Verisk Public Relations
201-232-4486
[email protected]

Brett Garrison
Edelman (for Verisk)
212-639-4903
[email protected]

Lyndsey Kleven
Nationwide Public Relations
614-507-0485
[email protected]

DALLAS, Dec. 08, 2020 (GLOBE NEWSWIRE) — Capital Senior Living Corporation (the “Company”) (NYSE: CSU) announced it has completed the operational transfer of its independent living community in Deer Park, Texas, to Fannie Mae, the holder of the community’s non-recourse debt. The Deer Park community is the first of 18 properties (the “Transition Communities”) the Company will transition to Fannie Mae under a cooperative process initiated in August, 2020.

As previously announced, the Company plans to enhance liquidity and improve operating cash flow by eliminating underperforming operations and focusing on its core owned and managed portfolio. The Company will transfer the operations and ownership of the 18 Transition Communities, all of which are either underperforming or are in underperforming loan pools, to Fannie Mae. The Company expects all 18 of the community transitions to be completed by the end of the first quarter of 2021. The Company receives a monthly management fee of approximately $0.2 million for managing the 18 communities.

The Company expects to extinguish $19.4 million in debt related to the Deer Park community when the legal transfer is complete, which is expected to occur in January 2021. The transfer of all 18 communities will reduce the Company’s debt by $217.7 million and improve annual cash flow by approximately $10 million.

“The transition of the Deer Park community is another step in our strategy to create a more focused, higher-performing portfolio while also reducing our liabilities and improving our liquidity,” said Kimberly S. Lody, President and Chief Executive Officer. “Our employees at Deer Park will be missed, and we thank them for their unwavering commitment to the safety, care and engagement of the community’s residents.”

As part of its SING (Stabilize, Invest, Nurture, Grow) strategy to improve its operating performance and financial foundation, the Company has taken a number of actions, including asset sales, lease terminations and community transitions to other owners and operators. Upon completion of all asset transitions, the Company’s portfolio is expected to consist of 68 senior living properties that primarily serve the fast-growing middle market senior population.

About Capital Senior Living

Dallas-based Capital Senior Living Corporation is one of the nation’s leading operators of independent living, assisted living and memory care communities for senior adults. The Company operates 105 communities that are home to more than 9,000 residents across 22 states and provide compassionate, resident-centric service and care as well as engaging programming.  The Company offers seniors the freedom and opportunity to successfully, comfortably and happily age in place.  For more information, visit www.capitalsenior.com or connect with the Company on Facebook.

For Further Information, Contact:
Kimberly Lody
(972) 308-8323
[email protected]

BASKING RIDGE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) — Verizon Business is expanding its Software Defined-Wide Area Network (SD WAN) portfolio to include the Silver Peak^®Unity EdgeConnect™ edge platform as a managed service offering.

Recently acquired by Aruba, a Hewlett Packard Enterprise company, the addition of the Silver Peak EdgeConnect platform to Verizon’s SD WAN portfolio provides enterprises with new optionality to transition to an SD WAN with integrated WAN Optimization environment for the management of business applications.

“There’s a transformative shift in the way that enterprises are looking to manage their WAN edge architecture, particularly in the context of today’s business climate. Legacy networks simply can’t keep up with the requirements of today’s cloud-first enterprises and the addition of the Silver Peak EdgeConnect platform to Verizon’s SD WAN portfolio is yet another achievement in driving value to businesses looking for rapid deployment of SD WAN and WAN Optimization experiences,” said Aamir Hussain, senior vice president of business products at Verizon Business.

Verizon’s SD WAN portfolio helps customers accelerate network transformation with advanced cloud control, centrally orchestrated and turnkey automated service assurance and management that is now integrated with Silver Peak^®Unity EdgeConnect™ appliances and SaaS-based controllers to deliver a seamless service experience. In addition, these capabilities can be delivered with other value-added capabilities such as Security, WAN Optimization and Verizon Wireless Connectivity.

“As enterprises continue to advance digital transformation initiatives, many are realizing that an intelligent WAN architecture is critical to achieving maximum value from existing and ongoing cloud investments,” said David Hughes, founder of Silver Peak and senior vice president of the WAN business at Aruba. “Enterprises can benefit from Verizon’s industry-leading managed services practice that now includes the Unity EdgeConnect SD WAN edge platform.”

Verizon was first to market with a global SD WAN offer and the first to deliver virtualized services globally and was recently recognized as a leader in the IDC MarketScape: Worldwide Managed SD WAN 2020 Vendor Assessment (Doc #US45837420, August 2020) report.

For three years in a row, Gartner has recognized Silver Peak as a Leader in the Magic Quadrant for WAN Edge Infrastructure*.

Gartner Disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Verizon

Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is celebrating its 20th year as one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $131.9 billion in 2019. The company offers voice, data and video services and solutions on its award winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control.

About Silver Peak

Silver Peak, recently acquired by Aruba, a Hewlett Packard Enterprise company, delivers the transformational promise of the cloud with a business-first networking model. The Unity EdgeConnect™ self-driving wide area network platform liberates enterprises from conventional WAN approaches to transform the network from a constraint to a business accelerant. More than 2,000 globally distributed enterprises have deployed Silver Peak SD-WAN solutions across 100 countries. Learn more at silver-peak.com.

VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at www.verizon.com/about/news/. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.

Media contact:

Kyle Ragonese (US)
[email protected]
732.236.3526

Nilesh Pritam (APAC)
+65.6248.6599
[email protected]

Clare Ward (EMEA)
+44.118.905.3501
[email protected]

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) — Porch.com, Inc. (“Porch” or “the Company”), a leading software and services platform reinventing the home services industry, today announced the appointments of Matthew Cullen to General Counsel and Secretary, and Joshua Steffan to VP and Group GM, Inspection and Real Estate.

Prior to joining Porch, Matt Cullen served in various roles at Expedia Group, Inc., most recently as Global Co-Head (Legal) of M&A and Integrations, where he was responsible for leading teams in acquisitions for aggregate deal value in excess of $10 billion, divestitures, company-wide complex projects (including COVID-19 response), and strategic sponsorships, as well as post-acquisition legal and integration matters. Prior to Expedia, Matt practiced law at Sullivan & Cromwell LLP and Davis & Gilbert LLP.

Joshua Steffan, who will lead Porch’s Home Inspection and Real Estate SaaS and services vertical, specializes in SaaS marketplace product strategy with over 15 years of experience growing digital businesses from startup to revenues of over $200 million. Prior to joining Porch, he was Chief Operating Officer at Home Bay where he was responsible for the real estate brokerage, closing and mortgage businesses and increased revenue by 40% year-over-year.

In July, Porch.com announced a merger agreement with PropTech Acquisition Corporation (NASDAQ: PTAC) (“PropTech” or “PTAC”), a special purpose acquisition company targeting businesses in the real estate technology industry that would result in Porch becoming a publicly listed company. With the expansion of its leadership team, Porch.com is well positioned to go public later this month.

“We’re extremely fortunate to have Joshua and Matt join our leadership team at such an exciting and important point in our Company’s history,” said Porch.com CEO, Chairman and Founder Matt Ehrlichman. “They are both extremely talented individuals, each with a pedigree of success throughout their career. I’m looking forward to working with each of them and building our own successes together in the months and years ahead.”

For detailed backgrounds on Porch’s executive leadership, please visit https://porch.com/about/team.

About


Porch.com

Seattle-based Porch, the vertical software platform for the home, provides software and services to more than 11,000 home services companies such as home inspectors, moving companies, real estate agencies, utility companies, and warranty companies. Through these relationships and its multiple brands, Porch provides a moving concierge service to homebuyers, helping them save time and make better decisions on critical services, including insurance, moving, security, TV/internet, home repair and improvement, and more. To learn more about Porch, visit porchcorp.com.

Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or PTAC’s or Porch’s future financial or operating performance. For example, projections of future revenue and adjusted EBITDA and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “or“ or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by PTAC and its management, and Porch and its management, as the case may be, are inherently uncertain Factors that may cause actual results to differ materially from current expectations include, but are not limited to: 1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive merger agreement with respect to the business combination; 2) the outcome of any legal proceedings that may be instituted against PTAC, the combined company or others following the announcement of the business combination and any definitive agreements with respect thereto; 3) the inability to complete the business combination due to the failure to obtain approval of the shareholders of PTAC, to obtain financing to complete the business combination or to satisfy other conditions to closing; 4) changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the business combination; 5) the ability to meet the Nasdaq’s listing standards following the consummation of the business combination; 6) the risk that the business combination disrupts current plans and operations of Porch as a result of the announcement and consummation of the business combination; 7) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; 8) costs related to the business combination; 9) changes in applicable laws or regulations; 10) the possibility that Porch or the combined company may be adversely affected by other economic, business and/or competitive factors; 11) Porch’s estimates of its financial performance; and 12) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in PTAC’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and the section entitled “Risk Factors” in PTAC’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither PTAC nor Porch undertakes any duty to update these forward-looking statements, except as otherwise required by law.

Press contact:

Tailwind Public Relations, LLC
Jeff Pecor
(206) 948-1482
[email protected]

Investor Relations contact:

Gateway Investor Relations
Cody Slach, Matt Glover
(949) 574-3860
[email protected]

PropTech Contact:

[email protected]

SALT LAKE CITY, Dec. 08, 2020 (GLOBE NEWSWIRE) — HireVue, the global leader in video interviewing, assessments, chatbot and recruiting automation technology, today announced it has appointed Andy Valenzuela as its new Chief Human Resource Officer (CHRO). Valenzuela brings a track record leading HR organizations that leverage technology to disrupt legacy processes, having worked for leading global brands including Dell, SunPower and SAP.

HireVue’s growth potential, overall industry momentum and HR tech’s impact on propelling the success of the modern enterprise attracted Valenzuela to the role. As CHRO, he will ensure that HireVue is fully leveraging its own technology, and he will serve as an ambassador of the product with HR peers around the world. Additionally, Valenzuela will continue growing the inclusive culture at HireVue that creates opportunities for employee growth and enables the organization to best serve its customers.

“HireVue is adding to our executive team an HR leader who can truly put himself in the shoes of our customers,” said Kevin Parker, Chairman and CEO of HireVue. “Andy’s experience building global teams that focus on innovation, customers, and business outcomes will help drive our global efforts by giving HireVue’s biggest asset, our people, the tools and skills needed to make an impact.”

Valenzuela joins at a time when HireVue is balancing tremendous growth, recently reaching 18 million video-based interviews and acquiring AllyO who have conducted 114M chat-based candidate engagements, against the backdrop of a global pandemic. His experience as an HR leader with a strong business and technology background will help build an HR organization that is passionate about helping the business deliver on its goals while at the same time deliver an exceptional employee experience for our existing employees and those candidates thinking about joining HireVue.

“As an HR leader, HireVue’s platform just makes sense – supporting efforts to rapidly fill job roles and reach a more diversified applicant pool,” said Valenzuela. “Our exceptional products are often an employee’s first experience of HireVue and of our customers’ business. I look forward to being an ambassador of HireVue’s product amongst my HR peers around the world whilst delivering an exceptional inclusive employee experience – leveraging and enhancing HireVue’s customer focused purpose driven culture.”

About
HireVue

HireVue is where hiring happens – transforming the way organizations discover, engage, and hire the best talent. Connecting companies and candidates anytime, anywhere, HireVue’s industry leading end-to-end hiring platform features video interviewing, assessments and conversational AI. HireVue has hosted more than 18 million video interviews and 114M chat-based candidate engagements for over 700 customers around the globe.

Press Contact

Andrea Judson-Torres
Highwire PR
310-592-6341
[email protected]